Freund's Adjuvant [clinicaltrials_resource:7543228d659dc9245e94e2a1d14dc64d]
Vaccination With Tetanus and KLH to Assess Immune Responses. [clinicaltrials:NCT00000105]A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant [clinicaltrials:NCT00001439]clinicaltrials:NCT00001703clinicaltrials:NCT00001827A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega [clinicaltrials:NCT00002359]clinicaltrials:NCT00003222clinicaltrials:NCT00003224Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery [clinicaltrials:NCT00003274]Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma [clinicaltrials:NCT00003339]Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma [clinicaltrials:NCT00003362]Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00003568]Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma [clinicaltrials:NCT00005841]Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma [clinicaltrials:NCT00006243]Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00006385]Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract [clinicaltrials:NCT00012246]Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma [clinicaltrials:NCT00019383]Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00019487]Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00019721]Vaccine Therapy in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00019994]Vaccine Therapy in Treating Patients With Melanoma [clinicaltrials:NCT00020358]Vaccine Therapy in Treating Patients With Metastatic Cancer [clinicaltrials:NCT00021164]Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment [clinicaltrials:NCT00022438]Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery [clinicaltrials:NCT00025181]Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer [clinicaltrials:NCT00030602]Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma [clinicaltrials:NCT00031733]Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma [clinicaltrials:NCT00032045]Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00062036]Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer [clinicaltrials:NCT00066729]clinicaltrials:NCT00071981Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00072085]Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma [clinicaltrials:NCT00077532]Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00079144]Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer [clinicaltrials:NCT00079157]clinicaltrials:NCT00085189Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma [clinicaltrials:NCT00089063]Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma [clinicaltrials:NCT00089193]Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery [clinicaltrials:NCT00089206]Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00091104]Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma [clinicaltrials:NCT00091143]clinicaltrials:NCT00091273
intervention browse [clinicaltrials_vocabulary:intervention-browse]
Freund's Adjuvant [clinicaltrials_resource:7543228d659dc9245e94e2a1d14dc64d]
Bio2RDF identifier
7543228d659dc9245e94e2a1d14dc64d
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:7543228d659dc9245e94e2a1d14dc64d
identifier
clinicaltrials_resource:7543228d659dc9245e94e2a1d14dc64d
title
Freund's Adjuvant
@en
type
label
Freund's Adjuvant [clinicaltrials_resource:7543228d659dc9245e94e2a1d14dc64d]
@en